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Background: Patients with hemophilia and inhibitors generally face greater disease burden compared to patients
without inhibitors. While raising awareness of relative burden may improve the standard of care for patients with
inhibitors, comparative data are sparse. Analyzing data drawn from the Cost of Haemophilia across Europe – a
Socioeconomic Survey (CHESS) study, the aim of this study was to compare the clinical burden of disease in
patients with severe hemophilia with and without inhibitors. Hemophilia specialists (N = 139) across five European
countries completed an online survey between January–April 2015, providing demographic, clinical and 12-month
ambulatory/secondary care activity data for 1285 patients. Patients with hemophilia who currently presented with
inhibitors and those who never had inhibitors were matched on baseline characteristics via propensity score
matching. Outcomes were compared between the two cohorts using a paired t-test or Wilcoxon signed-rank or
McNemar’s test.
Results: The proportion of patients who currently presented with inhibitors was 4.5% (58/1285). Compared to PS-
matched patients without inhibitors, patients with inhibitors experienced more than twice the mean annual number of
bleeds (mean ± standard deviation, 8.29 ± 9.18 vs 3.72 ± 3.95; p < .0001) and joint bleeds (2.17 ± 1.90 vs 0.98 ± 1.15;
p < .0001), and required more hemophilia-related (mean ± standard deviation, 1.79 ± 1.83 vs 0.64 ± 1.13) and
bleed-related hospitalizations (1.86 ± 1.88 vs 0.81 ± 1.26), hemophilia-related consultations (9.30 ± 4.99 vs 6.77 ± 4.47),
and outpatient visits (22.09 ± 17.77 vs 11.48 ± 16.00) (all, p < .001). More than one-half (53.5%) experienced moderate/
severe pain necessitating medication compared to one-third (32.8%) of patients without inhibitors (p = .01).
Conclusions: Patients with hemophilia and inhibitors exhibited greater clinical burden and higher resource utilization
compared to their peers without inhibitors. Strategies for improving the standard of care may alleviate burden in this
population.
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Congenital hemophilia is a life-long, X-linked hereditary
bleeding disorder caused by the deficiency of coagulation
factor VIII (FVIII) (hemophilia A) or factor IX (FIX)
(hemophilia B) [1]. More than 400,000 individuals are
afflicted globally [2] among whom, depending on the
population, approximately 33% to 50% have severe
hemophilia (FVIII or FIX activity level < 1% of normal)
[3]. Severe hemophilia typically manifests during child-
hood or adolescence, peak periods of growth and psycho-
social development, and is clinically characterized by a* Correspondence: Abiola.Oladapo@shire.com
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the joints and muscles [1, 4]. Without adequate manage-
ment, patients can suffer significant morbidity due to the
development of chronic arthropathy, disability, and im-
paired health-related quality of life (HRQoL). Additionally,
patients with severe hemophilia can sustain substantial so-
cietal losses owing to decreased school/work participation,
diminished productivity, and increased caregiver burden
[5–7]. The Social Economic Burden and Health-Related
Quality of Life of Patients with Rare Diseases (BUR-
QOL-RD) study recently examined a cross-section of
patients with hemophilia (N = 339) and caregivers (N = 62)
in Europe and found that 40% of patients reported some
degree of physical disability (Barthel Index score ≥ 91),
and over half (58.9%) of caregivers felt burdened [8].le is distributed under the terms of the Creative Commons Attribution 4.0
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placement therapies, such as recombinant anti-hemophilia
FVIII and recombinant FIX, which when administered
prophylactically are efficacious in preventing or reducing
the risk of bleeding and serious bleeding complications,
preserving joint function, and improving HRQoL and
productivity in patients with severe hemophilia [9–14].
Following exposure to exogenous FVIII/FIX, however,
approximately 10–30% of patients with severe hemophilia
A and 2–5% of those with severe hemophilia B develop
alloantibodies to FVIII and FIX, respectively [15]. These
inhibitors neutralize the coagulant activity of infused FVIII
or FIX, rendering patients refractory to standard factor
replacement therapy.
The development of a high-titer inhibitor (> 5 Bethesda
units) in particular poses significant treatment challenges
as achieving hemostasis becomes difficult with the admin-
istration of FVIII or FIX concentrates, necessitating the
use of bypassing agents to control and prevent bleeding
episodes. Current clinical guidance supports treatment
with bypassing agents prophylaxis (BAP) in patients with
severe hemophilia and inhibitors given its benefits over
on-demand treatment [16]. Compared to on-demand
treatment only, BAP reduces the frequency of joint bleeds,
prevents the development of new target joints, reduces
hospital admissions and school/work absences, and im-
proves HRQoL [17–22]. However, despite the benefits of
prophylaxis, and contrary to standard of care for patients
without inhibitors, the majority of patients with inhibitors
are still managed on-demand [23–25]. While it is gener-
ally accepted that patients with inhibitors face a higher
disease burden compared to patients without inhibitors,
limited comparative data exist in the literature to further
raise awareness of the crucial need to improve the stand-
ard of care for these patients relative to their peers with-
out inhibitors [26].
In this study, we used patient-level data from the Cost
of Haemophilia across Europe – a Socioeconomic Sur-
vey (CHESS) study [27] to compare bleed rates and
health resource utilization (HRU) in patients with severe
hemophilia with and without inhibitors. As frequent
evaluation of disease burden may assist in prioritizing
and improving patient care [23], the objective was to
quantify the real-world clinical burden of inhibitors in
this contemporary population with severe hemophilia.
Methods
Data collection
The CHESS study was conducted by the University of
Chester in partnership with the Haemophilia Society
(United Kingdom). The CHESS Steering Committee, a col-
laboration of treating clinicians, patients with hemophilia,
and representatives from academia and hemophilia soci-
eties, provided governance and oversight to ensure highstandards of quality. As such, the CHESS study represents
the first comprehensive, ‘bottom-up’ cost-of-illness study
that captured data from approximately 15% of patients
with severe hemophilia across five European countries
(EU5) – France, Germany, Italy, Spain, and the United
Kingdom. Its aim was to quantify the real-world societal
costs of severe hemophilia (factor level of < 1%) in the EU5
as a basis for understanding the potential impact of new
hemophilia treatments.
Between January and April 2015, a cross-section of
139 hemophilia specialists completed an on-line survey
and provided demographic, clinical, and 12-month retro-
spective ambulatory and secondary care activity data for
adult males (> 18 years) with severe hemophilia A (N =
996) or B (N = 289). Of the 1285 patients, 551 filled out
corresponding questionnaires and disclosed information
on out-of-pocket expenses and HRU. All patient-level
data were anonymized. The current analysis was re-
stricted to the patients and outcomes specified herein.
Outcome variables for the analysis were defined a priori
and were determined based on input from expert hema-
tologists and the hemophilia literature.
Identification of patients with and without inhibitors
The present analysis included the CHESS patients who
currently presented with inhibitors and those who had
never had an inhibitor. Patients with inhibitors were
identified from affirmative physician responses to the
query, “Is the patient currently diagnosed with an inhibi-
tor?” For patients without inhibitors, physicians
responded ‘Never’ to the question, “How many times
has the patient developed an inhibitor to factor replace-
ment therapies over their lifetime?”
Physician-reported information
Physicians provided data on patient demographics and
clinical characteristics (hemophilia type and comorbidi-
ties), 12-month bleed rates (including major, minor, and
joint bleeds), and the current status of the patient’s
hemophilia-related chronic pain. Comorbidities of interest
were selected by the CHESS Steering Committee. Minor
bleeds were defined as bleeds resolving within 24 h of
treatment and associated with mild pain, minimal swelling
and restriction of motion. Bleeds failing to respond to
treatment within 24 h and causing pain, effusion, and limi-
tation of motion were considered major bleeds. The
patient’s current pain level was described as: 1) No pain:
no functional deficit, no analgesic use (except with acute
hemarthrosis); 2) Mild pain: does not interfere with occu-
pation nor with activities of daily living (ADL), may re-
quire occasional non-narcotic analgesic; 3) Moderate pain:
partial or occasional interference with occupation or ADL,
uses non-narcotic medications; or 4) Severe pain: inter-
feres with occupation or ADL, requires frequent use of
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cated their current satisfaction with the patient’s prognosis
by selecting 1 of 3 responses: 1) Satisfied; 2) Not satisfied,
but I believe this is the best that can be realistically
achieved for this patient; or 3) Not satisfied, and I believe
better outcomes can be achieved for this patient.
Health resource utilization
Physicians reported the patient’s frequency of HRU over
the past 12 months, including hemophilia-related sched-
uled and non-scheduled consultations, hemophilia- and
non-hemophilia-related outpatient visits, and hemophilia-
and bleed-related hospitalizations. ‘Hemophilia-related’ ser-
vices pertained to treatment for hemophilia complications
or acute events, or planned surgeries.
Statistical analysis
Statistical analyses were performed using SAS 9.3 (SAS In-
stitute Inc., Cary, NC, US). Baseline patient demographics,
clinical attributes, and outcome measures were summa-
rized descriptively as the mean ± standard deviation (SD)
and median (range) for continuous variables and frequency
(percentage) for categorical variables. The two study co-
horts (i.e. inhibitors and non-inhibitors) were matched
using propensity score (PS) matching. In the PS matching,
a logistic regression model was used to predict the odds for
each patient to be enrolled in the inhibitor cohort, given
patient characteristics (e.g. age, body mass index, comor-
bidity). Age and body mass index were treated as inde-
pendent, continuous variables while race was dichotomized
as either white or non-white. Each comorbidity variable
was introduced into the model as a dichotomous variable.
A greedy propensity score matching approach, utilizing the
smaller caliper width that maintained the maximum sam-
ple size (caliper size of 0.035), was used to match a patient
in the inhibitor cohort to a patient in the non-inhibitor
cohort who had the closest propensity score within the spe-
cified caliper size and having the same type of hemophilia
(hemophilia A or B). To determine if balance was achieved
between the matched groups, differences between the
matched pairs were evaluated for each baseline variable
using a paired t-test or signed-rank test for continuous data
and the McNemar’s test for binary data. Finally, to address
the study objective, matched cohorts were then compared
on each outcome variable using a paired t-test or the
Wilcoxon signed-rank test for continuous variables and the
McNemar’s test or exact McNemar’s test for categorical
variables. A two-tailed p-value < 0.05 was considered statis-
tically significant.
Results
Baseline demographics and clinical characteristics
Fifty-eight (4.5%) of the 1285 CHESS patients currently
had an inhibitor, and 1091 (84.9%) had never developedan inhibitor (Table 1). The remaining patients (10.6%)
used to but no longer have inhibitors. Among the 1149
patients (i.e. those that currently have or never had in-
hibitors), the mean age was 35.5 ± 14.82 years; 87.6%
were white. Overall, 61.8% of patients were employed
full-time; 3.0% were either unable to work or were cur-
rently on a temporary leave of absence due to their
hemophilia. Nearly half (49%) of the patients had at least
one comorbidity of which, anxiety was most common
(14.1%), followed by depression (13.1%), and hyperten-
sion (12.1%).
In the unmatched cohorts, patients with inhibitors were
older (mean age, 41.90 ± 14.95 years vs 35.16 ± 14.74 years;
p < .0002) and had significantly higher frequencies of
anemia (p = .0135), diabetes mellitus (p = .0084), fibromyal-
gia (p = .0034), hypertension (p = .0134), and osteoarthritis
(p = .0175). Among the patients with relevant data, a
significantly greater proportion of patients with inhibitors
had attended college/graduate school (46.2% [12/26] vs
38.1% [168/441], respectively; p < .0001); however, fewer
patients with inhibitors worked full-time (28.6% [8/28] vs
38.8% [174/449]; p < .0001). Following PS matching
(Table 2), the demographic and clinical attributes appeared
statistically balanced between the cohorts (each, N = 58).
Bleeding outcomes following PS-matching
In the PS-matched analysis (Table 3), the mean annualized
bleed rate (ABR) in patients with inhibitors was more than
doubled that in patients without inhibitors (8.29 ± 9.18 vs
3.72 ± 3.95; p < .0001); 81% of patients with inhibitors had
experienced a major bleed (vs 37.9% of patients without
inhibitors; p < .0001), and all patients with inhibitors
(100%) had minor bleeds (vs 82.8% of patients without in-
hibitors; p = .0047). Similarly, the mean annualized joint
bleed rate (AJBR) in patients with inhibitors exceeded that
in patients without inhibitors by more than two-fold
(2.17 ± 1.90 vs 0.98 ± 1.15; p < .0001); 93.1% of patients
with inhibitors experienced joint bleeds during the
12 months compared to 55.2% of patients without inhibi-
tors (p < .0001). Chronic hemophilia-related pain was
more prevalent and significantly worse in the cohort with
inhibitors (Fig. 1). Moderate or severe chronic pain was
reported in more than half (53.4%) of patients with inhibi-
tors and in about one-third (32.8%) of patients without in-
hibitors (p = .0105). Outcomes in the unmatched cohorts,
including bleeding events, are shown in Additional file 1.
Health resource utilization
Fifty-six matched pairs contributed data to the analysis of
HRU. Over 12 months, patients with inhibitors had con-
sulted with hemophilia specialists significantly more often
than patients without inhibitors (mean, 9.30 ± 4.99 vs 6.77
± 4.47 visits; p = .0045). In addition, patients with inhibi-
tors had significantly higher outpatient visits (mean, 22.09
Table 1 Baseline characteristics of CHESS sample with severe hemophilia and unmatched cohorts with and without inhibitors
Characteristic All patients Patients who never developed
inhibitors
Patients with current
inhibitors
p-valuea
N = 1149 N = 1091 N = 58
Demographics
Age, years
Mean ± SD 35.50 ± 14.82 35.16 ± 14.74 41.90 ± 14.95 .0002
Median (range) 32 (18.00–88.00) 31 (18.00–88.00) 39.5 (18.00–80.00)
Race, N (%)
White 1007 (87.6) 958 (87.8) 49 (84.5) .6260
African 50 (4.4) 48 (4.4) 2 (3.4)
Asian-Indian subcontinent 37 (3.2) 34 (3.1) 3 (5.2)
Asian-Other 6 (0.5) 6 (0.5) 0 (0.0)
Middle Eastern 46 (4.0) 42 (3.8) 4 (6.9)
Other 3 (0.3) 3 (0.3) 0 (0.0)
White 1007 (87.6) 958 (87.8) 49 (84.5) .4532
Non-white 142 (12.4) 133 (12.2) 9 (15.5)
Body mass index
Mean ± SD 24.76 ± 3.25 24.73 ± 3.27 25.31 ± 2.78 .1140
Median (range) 24.57 (14.11–57.47) 24.51 (14.11–57.47) 25 (20.52–32.83)
Education, N (%)
None 15 (1.3) 12 (1.1) 3 (5.2)
Primary 51 (4.4) 49 (4.5) 2 (3.4)
Secondary 8 (0.7) 8 (0.7) 0 (0.0)
Undergraduate 76 (6.6) 73 (6.7) 3 (5.2)
Graduate 203 (17.7) 192 (17.6) 11 (19.0)
Did not answer 129 (11.2) 119 (10.9) 10 (17.2)
College or graduate
Yes 180 (38.5) 168 (38.1) 12 (46.2) <.0001
No 287 (61.5) 273 (61.9) 14 (53.8)
Employment status, N (%)
Full-time employed 182 (15.8) 174 (15.9) 8 (13.8)
Homemaker 1 (0.1) 1 (0.1) 0 (0.0)
Self-employed 3 (0.3) 1 (0.1) 2 (3.4)
Other: Not determined/not specified 4 (0.4) 4 (0.4) 0 (0.0)
Part-time employed 74 (6.4) 68 (6.2) 6 (10.3)
Retired 46 (4.0) 42 (3.8) 4 (6.9)
Student 84 (7.3) 82 (7.5) 2 (3.4)
Temporary leave of absence due to my hemophilia 6 (0.5) 5 (0.5) 1 (1.7)
Temporary leave of absence due to other reason(s) 6 (0.5) 6 (0.5) 0 (0.0)
Unable to work due to my hemophilia 29 (2.5) 23 (2.1) 6 (10.3)
Unable to work due to other reason(s) 2 (0.2) 2 (0.2) 0 (0.0)
Unemployed, able to work 40 (3.5) 40 (3.7) 0 (0.0)
Full-time employed
Yes 182 (38.2) 174 (38.8) 8 (28.6) <.0001
No 295 (61.8) 275 (61.2) 20 (71.4)
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Table 1 Baseline characteristics of CHESS sample with severe hemophilia and unmatched cohorts with and without inhibitors
(Continued)
Characteristic All patients Patients who never developed
inhibitors
Patients with current
inhibitors
p-valuea
N = 1149 N = 1091 N = 58
Hemophilia type, N (%)
Hemophilia A 894 (77.8) 847 (77.6) 47 (81.0) .5438
Hemophilia B 255 (22.2) 244 (22.4) 11 (19.0)
Comorbidities, N (%)
None 586 (51.0) 578 (53.0) 8 (13.8) <.0001
Alcohol dependence 39 (3.4) 35 (3.2) 4 (6.9) .1291
Anemia 65 (5.7) 57 (5.2) 8 (13.8) .0135
Anxiety 162 (14.1) 150 (13.7) 12 (20.7) .1389
Depression 151 (13.1) 140 (12.8) 11 (19.0) .1779
Diabetes mellitus 60 (5.2) 52 (4.8) 8 (13.8) .0084
Fibromyalgia 41 (3.6) 34 (3.1) 7 (12.1) .0034
Hepatitis B virus 20 (1.7) 19 (1.7) 1 (1.7) 1.0000
Hepatitis C virus 61 (5.3) 56 (5.1) 5 (8.6) .2282
Human immunodeficiency virus 31 (2.7) 28 (2.6) 3 (5.2) .2028
Hypertension 139 (12.1) 126 (11.5) 13 (22.4) .0134
Hypercholesterolemia 70 (6.1) 65 (6.0) 5 (8.6) .3931
Ischemic heart disease 19 (1.7) 16 (1.5) 3 (5.2) .0665
Obesity 63 (5.5) 60 (5.5) 3 (5.2) 1.0000
Osteoarthritis 68 (5.9) 60 (5.5) 8 (13.8) .0175
Osteoporosis 11 (1.0) 11 (1.0) 0 (0.0) 1.0000
Rheumatoid arthritis 9 (0.8) 9 (0.8) 0 (0.0) 1.0000
Other 18 (1.6) 16 (1.5) 2 (3.4) .2293
Abbreviations: CHESS, Cost of Haemophilia across Europe – a Socioeconomic Survey; SD, standard deviation
aP-values were derived from a paired t-test or Wilcoxon signed rank test for continuous post-match variables and the McNemar’s test or exact McNemar’s test for
categorical variables; p < .05 indicates statistical significance
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(1.79 ± 1.83 vs 0.64 ± 1.13; p < .0001) and bleed-related ad-
missions (1.86 ± 1.88 vs 0.81 ± 1.26; p = .0003) compared
to their peers without inhibitors (Fig. 2).
Physician satisfaction
Among the physicians of patients without inhibitors,
39.7% (23/58) were currently dissatisfied with their pa-
tient’s prognosis, of whom, 65.2% (15/23) believed that an
optimal prognosis had been attained, and 34.8% (8/23)
opined that better outcomes could be achieved. In con-
trast, 43.1% (25/58) of physicians of patients with inhibi-
tors were dissatisfied with the patient’s prognosis (Table 4).
Discussion
Over the past decade, prophylactic factor replacement
therapy has emerged as the standard of care for patients
with severe hemophilia in developed countries where
access to factor concentrates is unimpeded [28]. Still, the
development of an inhibitor remains universally, the mostserious treatment complication that poses a significant
barrier to successful care [15, 29–32]. Assessing the
burden of inhibitors in a contemporary population with
severe hemophilia may therefore provide insight into the
effectiveness of current treatment approaches, raise aware-
ness of unmet needs, and assist in improving patient care.
Real-world patient-level data from the CHESS study
afforded the opportunity to quantify the clinical burden
of inhibitors in a cross-section of 1285 patients repre-
senting approximately 15% of the population with severe
hemophilia in the EU5 [27]. The prevalence of current
inhibitors was 4.5%, which approached published esti-
mates (5–7%) for the hemophilia population, but was
lower than that for patients with severe hemophilia (12–
13%) [33]. Of the 1285 patients, 136 (10.6%) patients
had inhibitors in the past and did not currently present
with inhibitors. Considering that 84.9% of the CHESS
sample had never developed inhibitors, the cumulative
percentage with current and past inhibitors was 15.1%,
which more closely approximated the cited range.
Table 2 Baseline characteristics of PS-matched patients with and without inhibitors in the CHESS studya
Characteristic Patients who never developed inhibitors Patients with current inhibitors p-valueb
N = 58 N = 58
Demographics
Age, years
Mean ± SD 43.71 ± 17.17 41.90 ± 14.95 .4800
Median (range) 43 (18.00–88.00) 39.5 (18.00–80.00)
Race, N (%)
White 43 (74.1) 49 (84.5) .1573
Body mass index
Mean ± SD 24.92 ± 2.67 25.31 ± 2.78 .4072
Median (range) 25.08 (15.57–32.02) 25.00 (20.52–32.83)
Hemophilia type, N (%)
Hemophilia A 47 (81.0) 47 (81.0) 1.0000
Comorbidities, N (%)
Alcohol dependence 7 (12.1) 4 (6.9) .3173
Anemia 6 (10.3) 8 (13.8) .5271
Anxiety 13 (22.4) 12 (20.7) .8415
Depression 13 (22.4) 11 (19.0) .6374
Diabetes mellitus 7 (12.1) 8 (13.8) .7389
Fibromyalgia 3 (5.2) 7 (12.1) .1573
Hepatitis B virus 1 (1.7) 1 (1.7) 1.0000
Hepatitis C virus 9 (15.5) 5 (8.6) .2850
Human immunodeficiency virus 8 (13.8) 3 (5.2) .0956
Hypertension 15 (25.9) 13 (22.4) .6374
Hypercholesterolemia 7 (12.1) 5 (8.6) .5271
Ischemic heart disease 4 (6.9) 3 (5.2) .7055
Obesity 1 (1.7) 3 (5.2) .3173
Osteoarthritis 7 (12.1) 8 (13.8) .7815
Abbreviations: BMI body mass index, CHESS Cost of Haemophilia across Europe – a Socioeconomic Survey, PS propensity score, SD standard deviation
aPatients with current inhibitors were matched to patients who had never developed an inhibitor based on demographics (age, BMI, race) and comorbidity status
using propensity scores stratified by hemophilia type. Matching was performed using a preset caliper size of 0.035 to maintain the maximum sample size using
the smallest caliper width
bP-values were derived from a paired t-test or Wilcoxon signed rank test for continuous post-match variables and the McNemar’s test or exact McNemar’s test for
categorical variables; p < .05 indicates statistical significance
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were prevalent in nearly half (49%; 563/1149) of the total
unmatched sample of all patients with hemophilia.
Notably, the frequency of hypertension, which has been
associated with intracranial hemorrhage and atrial fibrilla-
tion in patients with hemophilia [36, 37], was significantly
higher in the inhibitor cohort (22% vs 11.5%; p = .0134).
This may have been due to the more advanced age of the
patients with inhibitors (mean, 41.9 vs 35.2 years) as
age-related conditions manifest over time.
In the PS-matching analysis, patients with inhibitors
were considerably more burdened compared to patients
without inhibitors as evidenced by a more than two-fold
increase in both the overall mean ABR and mean AJBR.
Over 12 months, the vast majority of patients withinhibitors had experienced major bleeds (81%) and joint
bleeds (93%). Compared to patients without inhibitors,
patients with inhibitors required not only significantly
more hemophilia- and bleed-related hospitalizations, but
more unscheduled visits with hemophilia specialists and
non-hemophilia-related outpatient visits. More than half
(53.5%) experienced chronic pain interference necessitat-
ing analgesic medication. The significantly higher bleed
rates in this cohort may have reflected the standard of
care in the inhibitor population which may have been
primarily focused on the on-demand or acute manage-
ment of bleeds. Although this remains to be confirmed
by examining treatment patterns in the CHESS study,
the finding that more than one-third (39.7%) of physi-
cians of inhibitor patients were dissatisfied with the
Table 3 Frequency of bleeds in PS-matched patients with and without inhibitors in the CHESS studya
Outcomes Patients who never developed inhibitors Patients with current inhibitors p-valueb
N = 58 N = 58
Bleeds in the past 12 months
(major and minor bleeds)
Mean ± SD 3.72 ± 3.95 8.29 ± 9.18 <.0001
Median (range) 3 (0.00–18.00) 6 (1.00–60.00)
Major bleeds, N (%)
Yes 22 (37.9) 47 (81.0) <.0001
No 36 (62.1) 11 (19.0)
Minor bleeds, N (%)
Yes 48 (82.8) 58 (100.0) .0047
No 10 (17.2) 0 (0.0)
Joint bleeds in past 12 months
Mean ± SD 0.98 ± 1.15 2.17 ± 1.90 <.0001
Median (range) 1 (0.00–4.00) 2 (0.00–8.00)
Yes, N (%) 32 (55.2) 54 (93.1) <.0001
No, N (%) 26 (44.8) 4 (6.9)
BMI body mass index, CHESS Cost of Haemophilia across Europe – a Socioeconomic Survey, PS propensity score, SD standard deviation
aPatients with current inhibitors were matched to patients who had never developed an inhibitor based on demographics (age, BMI, race) and comorbidity status
using propensity scores stratified by hemophilia type. Matching was performed using a preset caliper size of 0.035 to maintain the maximum sample size using
the smallest caliper width
bP-values were derived from a paired t-test or Wilcoxon signed rank test for continuous post-match variables and the McNemar’s test or exact McNemar’s test for
categorical variables; p < .05 indicates statistical significance. The McNemar’s test was not conducted for minor bleeds due to occurrence of event in 100% of
inhibitor cohort
Fig. 1 Physician-reported chronic hemophilia-pain by severity for PS-matched patients with and without inhibitors in CHESS studya. aPatients with
current inhibitors were matched to patients who had never developed an inhibitor based on demographics (age, BMI, race) and comorbidity
status using propensity scores stratified by hemophilia type. Matching was performed using a preset caliper size of 0.035 to maintain the maximum
sample size using the smallest caliper width. bP-value refers to the difference in the proportion of patients with moderate to severe pain between
cohorts and was derived from the McNemar’s test for categorical variables; p < .05 indicates statistical significance. Abbreviations: BMI, body mass
index; CHESS, Cost of Haemophilia across Europe – a Socioeconomic Survey; PS, propensity score
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Fig. 2 HRU frequency over 12 months for PS-matched patients with and without inhibitors in CHESS studya. a‘N’ pertains to number of patients
in each cohort after PS-matching. Patients with current inhibitors were matched to patients who had never developed an inhibitor based on
demographics (age, BMI, race) and comorbidity status using propensity scores stratified by hemophilia type. Matching was performed using a preset
caliper size of 0.035 to maintain the maximum sample size using the smallest caliper width. bP-values were derived from a paired t-test or Wilcoxon
signed rank test for continuous post-match variables; p< .05 indicates statistical significance. Abbreviations: BMI, body mass index; CHESS, Cost of
Haemophilia across Europe – a Socioeconomic Survey; HRU, health resource utilization; PS, propensity score; SD, standard deviation
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Table 4 Physician-reported satisfaction regarding PS-matched
patients with and without inhibitors in the CHESS studya
Outcomes Patients
who never
developed
inhibitors
Patients
with current
inhibitors
p-valueb
N = 58 N = 58
Physician responses to question, “Which of the following best
describes your current satisfaction with the prognosis for this
haemophilia patient?” N (%)
N 58 58
Satisfied 35 (60.3) 33 (56.9)
Not satisfied, but I believe this is
the best that can be realistically
achieved for this patient
15 (25.9) 14 (24.1)
Not satisfied, and I believe better
outcomes can be achieved for
this patient
8 (13.8) 11 (19.0)
Satisfied 35 (60.3) 33 (56.9) .6831
Not satisfied 23 (39.7) 25 (43.1)
Abbreviations: BMI body mass index, CHESS Cost of Haemophilia across Europe
– a Socioeconomic Survey, PS propensity score
aPatients with current inhibitors were matched to patients who had never
developed an inhibitor based on demographics (age, BMI, race) and
comorbidity status using propensity scores stratified by hemophilia type.
Matching was performed using a preset caliper size of 0.035 to maintain the
maximum sample size using the smallest caliper width
bP-values were derived from a paired t-test or Wilcoxon signed rank test for
continuous post-match variables, and the McNemar’s test or exact McNemar’s
test for categorical variables; p < .05 indicates statistical significance
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lenge of managing adult patients with inhibitors.
The incremental clinical burden of inhibitors observed
in the CHESS cohort mirrored the trends observed in the
European Study on Orthopaedic Status of Haemophilia
Patients (ESOS), a cross-sectional, case-control study of
patients with hemophilia enrolled during the period from
March 2004 to December 2005. In the ESOS, patients
aged 14–35 years who had severe hemophilia with inhibi-
tors (N = 38) had significantly worse joint pain (p < .05),
more mobility problems (p < .001), and poorer orthopedic
scores (p < .05) than patients without inhibitors (N = 49)
[15]. Greater proportions of patients with inhibitors in the
ESOS, irrespective of age, were also hospitalized for mus-
culoskeletal bleeding or orthopedic procedures (16% of
patients aged 14–35 years and 27% of patients aged 36–
65 years [N = 41]) compared to patients without inhibitors
(4%). The mean AJBR was comparable between the inhibi-
tor cohorts and controls, although patients with inhibitors
had significantly worse orthopedic scores [15]. Although
orthopedic status was not analyzed in the CHESS sample,
the higher AJBR in the inhibitor cohort (vs non-inhibitor
cohort) may nonetheless signify increased morbidity as
chronic joint bleeds have been associated with a greater
frequency of orthopedic complications [15]. Comparing
orthopedic status and the associated HRU between the
PS-matched CHESS samples in future research may moreprecisely quantify the burden of inhibitors in the contem-
porary hemophilia population.
Study limitations are noted. First, as in all questionnaire-
based research, the validity of the survey responses was
subject to the respondents’ interpretation, recall, and ac-
curacy in recording information. However, this limitation
pertains primarily to the patients’ responses as the physi-
cians provided data obtained from their retrospective chart
reviews. Second, although we adjusted for baseline covari-
ates, unmeasured confounding factors may have accounted
for some differences in the outcomes between the PS-
matched cohorts. However, the increased clinical burden
of disease in the inhibitor cohort was consistent with
observations in prior studies [15, 38, 39]. Third, due to the
cross-sectional study design, the prevalence of current
inhibitors represented a ‘point-in-time’ estimate which
may have overestimated or underestimated the true bur-
den of inhibitors. Further, we did not compare orthopedic
status, which may have further differentiated the cohorts;
however, a future analysis including this endpoint may be
considered. Finally, although data were collected across
the EU5, we did not conduct country-specific analyses due
to the small sample size.Conclusions
Patients with inhibitors in the CHESS study exhibited
greater clinical burden and utilized significantly more
health resources compared to their peers without inhibi-
tors. Physician dissatisfaction with their patients’ prog-
nosis underscores the need for improving the standard
of care for patients with inhibitors. Strategies for indi-
vidualizing and improving care may also reduce the
clinical burden of disease in this population.Additional file
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